MYL-1401H

BIOLOGICAL2 trials

Sponsors

Mylan Inc.

Conditions

Breast NeoplasmsChemotherapy-Induced Febrile NeutropeniaHealthy Volunteers

Phase 1

Pharmacokinetic / Pharmacodynamic Study Comparing MYL-1401H, EU-sourced Neulasta and US-licensed Neulasta

CompletedNCT02479646

Mylan Inc.Healthy Volunteers

Start: 2014-09-30End: 2015-06-30Updated: 2022-02-14

Phase 3

Efficacy and Safety Study With MYL-1401H and Neulasta

CompletedNCT02467868

Mylan Inc.Breast Neoplasms, Chemotherapy-Induced Febrile Neutropenia

Start: 2015-03-31End: 2016-02-29Updated: 2022-02-14

Related Papers

Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia.

2019-03-0115 citations